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INTRODUCTION
When tissue is injured by microbial invasion or sterile injury, several kinds of immune cells infiltrate damaged tissue and induce acute inflammation in a coordinated manner. The inflammatory response is critical for the elimination of microorganisms. However, once the causes of tissue injury are eliminated, the acute inflammatory response should shift to tissue repair and regeneration processes. Macrophages play critical roles in both the propagation and resolution of inflammation (1) . In the acute inflammatory phase, tissue-resident macrophages and infiltrating monocytes coordinately induce inflammation by secreting inflammatory cytokines and chemokines. In contrast, these cells also contribute to tissue repair and regeneration during the recovery phase of inflammation (2) . For example, in a mouse model of liver injury, the depletion of CD11b + macrophages late in the course of inflammation impairs tissue regeneration (3) . Newly infiltrated monocyte-derived macrophages exacerbate ischemiainduced kidney injury, whereas blockade of the in situ proliferation of these macrophages inhibits tubular repair (4) . These findings suggest the emergence of phenotypically distinct macrophages that contribute to tissue repair and regeneration after tissue injury. However, the origin of these macrophages with distinct phenotypes is not fully understood. In particular, it remains unclear whether these tissue repair-driving macrophages are derived from circulating precursors or result from the phenotypic conversion of proinflammatory macrophages in situ (5) .
It is generally considered that the monocyte-macrophage lineage has high plasticity and can readily change phenotypes in response to environmental cues (6, 7) . This concept is supported in part by observations that bone marrow-derived macrophages exhibit immunologically polarized states in vitro (5, 8, 9) , that is, two distinct macrophage subsets are differentiated from monocyte-macrophage precursor cells in bone marrow by different sets of cytokines. Classically activated macrophages, also known as M1 macrophages, are induced by lipopolysaccharide (LPS; with or without interferon-) and produce proinflammatory cytokines and reactive oxygen intermediates, and these macrophages exhibit microbicidal and tumoricidal activities. Alternatively activated macrophages, also known as M2 macrophages, differentiate in response to interleukin 4 (IL-4; with or without IL-10) stimulation. M2 macrophages show anti-inflammatory activity and enhanced expression of genes related to tissue repair and remodeling. On the basis of this classification of macrophage subsets, much effort has been made to understand the phenotypes and functions of tissue-resident or infiltrating macrophages in a variety of pathological conditions. Although tissue macrophages exhibit properties of M1 or M2 under certain conditions in vivo (2, 9, 10) , most macrophages exhibit mixed or atypical phenotypes that do not strictly fit M1 or M2 phenotypes, suggesting that a greater complexity of macrophage differentiation or activation occurs in vivo (11) (12) (13) . Unlike M2 macrophages that are generated in vitro, details remain unknown about the origin and function of immunoregulatory or tissue repair-promoting macrophages in vivo.
Here, we show that the resolution of inflammation prompts precursors of Ly6C hi monocytes in bone marrow to differentiate into Ym1-expressing monocytes endowed with the ability to accelerate tissue regeneration. These findings indicate that the emergence of immunoregulatory macrophages in the recovery phase of tissue injury is attributed to not only the phenotypic conversion of macrophages in situ but also the migration of Ym1 + monocytes produced de novo in bone marrow.
RESULTS

Identification of Ym1-expressing cells in peripheral blood and other tissues
Ym1 is known to be expressed in myeloid cell lineages and generally used as a marker for alternatively activated M2 macrophages. However, it remains obscure what kinds of cell populations and under which conditions those cells actually express Ym1 in vivo. To visualize Ym1-expressing cells in mice, we generated mice that harbor the Venus gene in the Chil3 (Ym1-coding gene) loci (Ym1-Venus mice; fig. S1, A and B). We first sought to determine what kinds of tissueresident macrophages or dendritic cells expressed Ym1-Venus in various tissues of these mice. As shown in Fig. 1A , tissue-resident macrophages and dendritic cells were Ym1-Venus-negative in lymph nodes, spleen, colon, liver, and peritoneal cavity. The only exception was resident macrophages in the lung. Lung-resident macrophages consisted of CD11c   +   CD64  + alveolar macrophages and CD11b   +   MHCII   + interstitial macrophages, and only the former expressed Ym1-Venus. We next sought to identify Ym1-Venus-positive cells in the peripheral blood of these mice. It is reported that neutrophils expressed Ym1 (14, 15) , and consistent with these reports, most of Ly6G + neutrophils were Ym1-Venus-positive (Fig. 1, B and C) . We also found that neutrophils expressed Ym1-Venus in the spleen (Fig. 1D) . In bone marrow, the expression levels of Ly6G are gradually up-regulated, whereas those of c-Kit are down-regulated in the course of neutrophil differentiation (16) . As shown in fig. S2A , not only Ly6G hi mature neutrophils but also c-Kit dull Ly6G-negative to -low immature neutrophils expressed Ym1-Venus. Immature neutrophils expressed higher levels of Ym1 mRNA than mature neutrophils, indicating that Ym1 is expressed from the early stages of the neutrophil differentiation ( fig. S2B ). Expression of Ym1-Venus was not detected in eosinophils, B cells, T cells, natural killer (NK) cells, or NKT cells in peripheral blood or the spleen (Fig. 1, B to D) . In addition to neutrophils, we noticed that a small population (5%) of CD115 +
Ly6C
hi peripheral blood and splenic monocytes expressed Ym1-Venus, whereas CD115 + Ly6C lo monocytes did not express Ym1-Venus (Fig. 1, B (Fig. 2B) . We further evaluated the Ym1-Venus expression in various hematopoietic progenitors in Ym1-Venus mice and found that common myeloid progenitor (CMP), granulocyte-macrophage progenitor (GMP), and megakaryocyte-erythroid progenitor (MEP) did not express Ym1-Venus (Fig. 2C) . GMP gives rise to macrophage-dendritic cell progenitor (MDP), and monocytes are differentiated from MDP through the common monocyte progenitor (cMoP) (18) . We found that neither MDP nor cMoP expressed Ym1-Venus, and Ym1-Venus expression was detected in monocytes only after these cells lost c-Kit expression (R4, Fig. 2D ). These results indicate that monocytes express Ym1 at the final stage of their differentiation in bone marrow under steady-state conditions.
Expansion of Ym1
+
Ly6C
hi monocyte subpopulation in the late phase of inflammation Ly6C hi monocytes infiltrate into an inflammatory site in response to microbial invasion or tissue injury and regulate inflammation. Thus, we sought to determine the dynamics of Ym1-Venus-positive cells in CD115 +
hi monocytes during inflammation. Serum concentrations of inflammatory cytokines, including tumor necrosis factor- (TNF) and IL-6, increased 2 hours after LPS injection and rapidly returned to baseline levels by 24 hours (fig. S3 ). Both the number and proportion of blood neutrophils increased 24 hours after LPS injection and returned to normal levels after 72 hours (Fig. 3A) . In contrast, the proportion of Ly6C hi monocytes remained unchanged 24 hours after LPS injection but increased and occupied about 6% of blood leukocytes after 48 hours (Fig. 3A) . The Ym1-Venus + Ly6C hi monocyte subpopulation expanded markedly during the late phase of inflammation (Fig. 3, A and B) , such that the proportion of the Ym1-Venus-positive subpopulation in Ly6C hi monocytes increased to 10% 24 hours after LPS injection and reached about 50% after 48 hours. The Ym1-Venus-positive subpopulation decreased to 24% in Ly6C hi monocytes, and 5% of Ly6C lo monocytes became Ym1-Venus-positive 72 hours after LPS injection, suggesting that Ym1-Venus + Ly6C
hi monocytes may become Ly6C lo monocytes. We also confirmed that 54% of the Ly6C hi monocytes expressed Ym1-Venus in the spleen 48 hours after LPS injection (Fig. 3C) .
Consistent with these findings in peripheral blood and spleen, the proportion of Ym1-Venus-positive cells in the Ly6C hi monocytes started to increase in bone marrow 24 hours after LPS injection and reached about 40% after 48 hours (Fig. 3D ). These Ym1-Venus 
CD11c
− monocyte subpopulation, the same as that observed in the bone marrow of naïve mice (Fig. 3E) . Quantitative polymerase chain reaction (PCR) analysis revealed that these Ym1-Venus + Ly6C hi monocytes actually exhibited higher Ym1 mRNA expression compared with Ym1-Venus-negative monocytes in bone marrow (Fig. 3F) . Together, we concluded that the Ym1-expressing Ly6C hi monocyte subpopulation expands markedly in the bone marrow during the late phase of inflammation. (Fig. 4 , D and E). In agreement with the shared characteristics described above, there were small differences between these subsets in terms of the expression levels of inflammatory genes, transcription factors ( fig. S4, A and B) , or monocyte/macrophage signatures (Fig. 4E) . One of the few macrophageassociated genes highly expressed in Ym1-Venus-positive monocytes was Marco, a scavenger receptor required for combating pneumococcal infection (Fig. 4 , E and F) (23) . Ym1 is considered a marker for alternatively activated (M2) macrophages. Ym1-Venus-positive monocytes expressed higher levels of Ym1 mRNA than Ym1-Venus-negative monocytes (Fig. 4 , E and F). However, none of other M1-or M2-related gene expression was down-or up-regulated in Ym1-Venuspositive monocytes when compared with Ym1-Venus-negative ones (Fig. 4E ). Principal components analysis (PCA) showed much greater distance between the Ym1 + or Ym1 − monocytes and neutrophils than between the naïve monocytes (Fig. 4D) . To highlight the difference between Ym1 + and Ym1 − monocytes, we further performed PCA between three monocyte subsets ( fig. S4C ). This analysis extracted several neutrophil-related genes as loading factors that discriminate Ym1 + and Ym1 − monocytes. The expression of several neutrophil-related genes including Ltf (lactoferrin-coding gene) and Mmp9 was enhanced in Ym1-Venus-positive monocytes (Fig. 4 , E and F). The expression levels of other neutrophil-related genes, such as Ly6g5b and Retnlg (resistin-like gamma-coding gene), were similar between two subpopulation (Fig. 4 , E and F), thereby excluding the possibility of neutrophil contamination in sorted Ym1-Venuspositive monocytes. These results suggest that Ym1-Venus-positive monocytes are indeed a subpopulation of monocytes but have some characteristics of neutrophils.
Ym1
To further reveal the functional differences between Ym1-Venus-positive and Ym1-Venus-negative monocytes, we purified each monocyte subpopulation from LPS-treated mice and restimulated these cells with LPS ex vivo. As shown in Fig. 5A , Ym1-Venus-positive monocytes produced lower levels of proinflammatory cytokines and a higher level of anti-inflammatory cytokine IL-10 than Ym1-Venus-negative monocytes. The monocytes did not produce detectable levels of cytokines unless restimulated ex vivo. As shown in Fig. 5B , the transfer of Ym1-Venus − Ly6C hi monocytes increased serum IL-6 concentrations in LPS-injected recipient mice. On the other hand, the transfer of Ym1-Venus It is reported that monocyte-derived alternatively activated macrophages promote the differentiation of CD4 + Foxp3 + regulatory T cells (24) . Thus, we treated splenic T cells with culture media of Ym1-Venus + Ly6C hi monocytes or Ym1-Venus − Ly6C hi monocytes prepared from LPS-treated mice and stimulated these cells with anti-CD3 antibody (Ab) and anti-CD28 Ab. As shown in 
Ly6C
hi monocytes are essential for recovery from tissue injury Because the proportion of Ym1-Venuspositive monocytes increases in the late phase of systemic inflammation, we next examined the dynamics of Ym1-Venuspositive monocytes during local inflammation. The administration of dextran sodium sulfate (DSS) in drinking water induces epithelial injury that manifests as a clinical symptom of acute colitis in mice. This model is considered dependent on innate immunity because colitis develops in lymphocyte-deficient mice. In this experimental model, discontinuation of DSS administration terminates inflammation and initiates the regeneration of the epithelial barrier. Thus, we can analyze both acute and recovery phases of inflammation using this model. We administered DSS in drinking water to Ym1-Venus mice for 5 days, followed by discontinuation of DSS administration, and examined blood cell expression of Ym1-Venus during the course of inflammation. During the early inflammatory phase, neutrophils constantly expressed Ym1-Venus, whereas the proportion of Ym1-Venus + Ly6C hi monocytes remained low (Fig. 6 , A and B). However, 3 days after the discontinuation of DSS administration (day 8), a substantial number of Ym1-Venus-positive monocytes appeared in the Ly6C hi population, accounting for ~30% of this monocyte subpopulation during the recovery phase of colitis. Consistent with these findings, a substantial number of Ym1-Venus-positive monocytes also appeared in the Ly6C hi population during the recovery phase of inflammation in spleen ( fig. S5 ) and bone marrow (Fig. 6C ). We examined whether these monocytes can infiltrate into sites of inflammation. Gut macrophages and monocytes can be classified on the basis of the differential expression of Ly6C and CD64, such that Ly6C hi CD64 lo monocytes decrease their Ly6C expression while progressively increasing CD64 expression as they differentiate into resident macrophages (25) . We found that the frequency of Ym1-Venus-positive cells among Ly6C hi CD64 lo monocytes in the inflamed colon expanded not on day 5, but on day 9, whereas only a small proportion of Ly6C int C-D64 int monocytes and none of Ly6C lo CD64 hi macrophages were Ym1-Venus-positive (Fig. 6D) . Given that Ly6C are reported to become Ly6C lo CD64 hi macrophages after they infiltrate into the colon, Ym1 expression may gradually decrease in Ym1-Venus-positive monocytes during developmental maturation in the colon.
hi monocytes exhibit inflammatory signature only after infiltrating into inflamed colons of colitic mice (26) . Then, we purified Ym1-Venus + Ly6C hi and Ym1-Venus − Ly6C hi monocytes from the colon in DSS-induced colitis mice (day 9) and compared gene expression between the two populations. We found that Ym1-Venus-positive monocytes in inflamed colon expressed low levels of Il-6 and high levels of Il-10 compared with Ym1-Venus-negative monocytes, indicating the immunoregulatory phenotype of Ym1-Venus-positive monocytes (Fig. 6E) . However, Ym1-Venus-positive monocytes showed higher expression of Nos2, a gene signature associated with a proinflammatory phenotype or classically activated (M1) macrophages as well. Although nitric oxide generates reactive oxidants capable of causing collateral tissue injury, nitric oxide also is reported to play a role in tissue regeneration (27, 28) . Therefore, Nos2 expression in Ym1-Venuspositive monocytes can be associated with accelerated recovery from DSS-induced colitis in mice. Ym1-Venus-positive monocytes showed higher expression of inflammation-related genes, such as three monocytes. *P < 0.05, **P < 0.01, ****P < 0.0001. Tlr2 and Nod2, suggesting that these cells exhibit mixed gene expression profile (Fig. 6E ). In addition, we found that Ym1-Venuspositive monocytes expressed higher levels of Slpi, which is essential for resolution of inflammation and tissue repair (Fig. 6E) (29) .
The expansion timing and gene expression profile of Ym1-Venus-positive monocytes prompted us to consider the possibility that these cells are involved in the resolution of inflammation and tissue regeneration in the inflamed colon. To examine this concept, we generated mice harboring the diphtheria toxin receptor (DTR) gene in the Ym1 loci (Ym1-DTR mice, fig. S6, A and B) . Diphtheria toxin (DT) injection deleted only neutrophils and not monocytes in naïve mice ( fig.  S6, C and D) . However, when these mice were injected with DT 48 hours after LPS injection, the proportion of monocytes was decreased from 4 to 2% (fig. S7, A  and B (Fig. 6F) . Histological examination revealed prolonged inflammation and delayed tissue repair in the absence of Ym1-positive cells (Fig. 6G) . Tissue cytokine levels were also increased by the deletion of Ym1-positive cells (Fig. 6H) . In addition, the number of IL-10-producing T cells in Ym1-DTR mice was lower than that in WT mice ( fig. S7E ). Because neutrophils are known to perform the critical tasks of tissue repair in a sterile liver injury model (30), we examined the contribution of Ym1 + neutrophils to the recovery from DSS-induced colitis by selectively deleting neutrophils by anti-Ly6G Ab injection in the recovery phase of colitis. Deletion of only neutrophils had no effect on recovery from colitis ( fig. S8) One-way ANOVA, n = 4 to 6. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Each symbol represents an individual sample. Iso, isotype control; IgG1, immunoglobulin G1. cMoP expressed Ym1-Venus in the bone marrow of LPS-injected mice (about 6% of R2 fraction; Fig. 7A (Fig. 7B) . Next, we transferred GP or cMoP from CD45.2 + naïve Ym1-Venus mouse bone marrow into LPS-injected CD45.1 + congenic mice and analyzed blood cells in the recipient mice 48 hours later. As shown in Fig. 7C , the transfer of cMoP, but not GP, gave rise to Ym1-Venus + Ly6C hi monocytes. It has been reported recently that monocytes can be differentiated not only from MDP but also directly from GMP (32) . Adoptive transfer of GMP or MDP prepared from the bone marrow ( fig. S9 ) of Ym1-Venus mice into WT mice revealed that GMP, but not MDP, has the ability to generate Ym1 + monocytes (Fig. 7D) . We examined the possibility that Ym1-Venus-negative monocytes could convert directly into Ym1-Venus-positive monocytes. Ym1-Venus-negative monocytes were isolated from the bone marrow of naïve Ym1-Venus mice (CD45.2 + ) and transferred into CD45.1 + congenic mice that were preinjected with LPS. CD45.2 + monocytes were detected in the Ly6C hi monocyte population but did not become Ym1-Venus-positive (Fig. 7E) , suggesting that Ym1-Venus-positive monocytes are not derived from Ym1-Venus-negative counterpart but may be from monocyte precursor cells probably programed to become Ym1-Venuspositive monocytes.
To further clarify the mechanisms by which cMoP differentiates into Ym1-Venus + Ly6C
hi monocytes, we stimulated cMoP from Ym1-Venus mice with various cytokines ex vivo and examined Ym1-Venus expression in these cells. In the presence of macrophage colonystimulating factor (M-CSF), cMoP proliferated and mainly differentiated into F4/80 + cells that did not express Ym1-Venus (Fig. 7F ). In contrast, granulocyte-macrophage CSF (GM-CSF) exposure of cMoP gave rise to F4/80 + cells and Ly6C hi F4/80 − cells, which included Ym1-Venus-positive cells (Fig. 7, F and G) . M-CSF enhanced the GM-CSF-induced cMoP differentiation into Ly6C hi F4/80 − cells, which included Ym1-Venus-positive cells. We also found that IL-3 with M-CSF gave rise to the same differentiation pattern as observed with GM-CSF + M-CSF. Ym1 expression was not induced by IL-4 or IL-10. These results suggest that the GM-CSF and/or IL-3 axis is involved in the differentiation of cMoP into Ym1-positive immunoregulatory monocytes.
DISCUSSION
It is generally considered that monocytes recruited to an injured site exhibit the proinflammatory phenotype and contribute to the propagation of inflammation. In the case of colitis, blockade of CCR2 inhibits monocyte migration into inflamed colon, and consequently ameliorates DSS-induced colitis, demonstrating the proinflammatory roles of migrating monocytes in the early phase of inflammation (26) . CCR2 deficiency also results in the amelioration of fibrosis associated with epithelial injury in the lung (33) . On the other hand, the roles of monocytes in the resolution of inflammation and tissue regeneration have been highlighted recently. Lucas et al. (34) reported that the deletion of macrophages and monocytes in different phases of a skin injury model yields distinct outcomes. In this model, the deletion of macrophages and recruited monocytes in the tissue formation phase causes severe hemorrhage in the wounded tissue and stagnation of regeneration. Grainger et al. (35) demonstrated that Ly6C hi monocytes in inflamed colon of a Toxoplasma gondii infection model adopted a mixed phenotype, acquiring both inflammatory and regulatory features, and inhibited neutrophil activation by producing prostaglandin E2. In this infection model, CCR2 deficiency caused severe mucosal inflammation by activated neutrophils, demonstrating the regulatory functions of monocytes at the inflamed site. Very recently, atypical monocytes that are involved in detrimental fibrosis of the lung were identified (36) . This monocyte population expanded not in the acute inflammatory phase but in the late fibrotic phase of bleomycin-induced lung injury. These reports demonstrated that monocytes play opposite roles in a context-or time-dependent manner. In this study, we identified a subpopulation of Ly6C hi monocytes whose phenotype is biased toward immune regulation. This Ym1 + Ly6C hi monocyte subpopulation, expanding during the recovery phase of tissue injury or inflammation, contributes to the resolution of inflammation in a mouse model of colitis. These results demonstrate that monocytes/macrophages responsible for the resolution of inflammation and tissue repair are, at least in part, derived from distinct circulating monocyte subsets generated in bone marrow. We showed that Ym1
hi monocytes in the inflamed colon expressed higher levels of IL-10 than Ym1 − Ly6C
hi monocytes, suggesting their intrinsic ability to directly regulate inflammation. However, we cannot exclude the possibility that Ym1
hi monocytes have some additional ability to help the resident macrophages heal injured tissue. Very recently, Yáñez et al. (32) reported that monocytes with different characters were derived from bone marrow progenitors via two independent pathways. The relationship between these monocytes and Ym1 + monocytes in this manuscript needs to be clarified. Under inflammatory conditions, signals from an inflamed site stimulate myeloid cells and their progenitors in bone marrow and alter myelopoiesis both in quantity and in quality to meet the demands in the periphery (37) (38) (39) . For example, granulocyte CSF (G-CSF) is locally produced at an inflamed site in lung infection and acts to enhance the release of neutrophils from bone marrow to periphery (40) . During fungal infection, granulopoiesis in bone marrow takes place in a CCAAT/enhancer binding protein (C/EBP)-dependent manner, whereas C/EBP is involved in granulopoiesis under steady-state conditions, suggesting that a certain signal produced at the infected sites makes an influence on hematopoiesis in bone marrow (41) . In Listeria monocytogenes infection, monopoiesis in bone marrow is enhanced presumably by bacterial components in a Toll-like receptor (TLR)-dependent manner (42) . All these findings demonstrate the roles of locally produced cytokines or bacterial components at the inflamed site on emergence of hematopoiesis. In this study, we found that the Ym1 + Ly6C
hi monocyte subpopulation expanded only in the recovery phase of inflammation or tissue injury. This suggests the involvement of environmental signals from the inflamed site in expanding of this monocyte subpopulation. The in vitro differentiation assay in this study suggests the involvement of GM-CSF/IL-3 signaling in Ym1 + Ly6C hi monocyte differentiation in bone marrow (Fig. 7, F and G monocytes is regulated not only by a mechanism that controls the differentiation of myeloid cells in bone marrow but also by environmental signals at injured sites. Macrophages are characterized by considerable diversity and plasticity and have the ability to change their phenotype in response to local signals (43) (44) (45) . Under inflammatory conditions, Ly6C hi monocytes acquire the proinflammatory phenotype through TLR or nucleotide-binding oligomerization domain (NOD) after infiltrating into the inflamed colon (26) . Seo et al. (46) also reported that specific kinds of microbiota activate NLRP3 inflammasome in recruited monocytes and induce IL-1 release in infiltrating monocytes in the inflamed colon. All these reports demonstrate that monocytes and macrophages have the ability to alter their phenotype flexibly in response to environmental cues derived from microbiota or damaged cells. In this regard, it is most likely that injured tissues or dying cells produce or release a certain molecule to dictate the phenotype of Ym1 + Ly6C
hi monocytes during the recovery phase of tissue injury. It is reported that the phagocytosis of cell debris stimulates macrophages to produce Wnt3a and Wnt7a, which are involved in hepatic regeneration by regulating hepatic progenitor cell fate (47) . This finding suggests that dead cell clearance may act as a trigger to dictate the phenotype of Ym1 + Ly6C hi monocytes. In any case, the molecular mechanisms by which macrophages adopt a specific phenotype during tissue recovery should be revealed to understand the roles of immunoregulatory monocytes in injured tissue. In this study, we could not identify an environmental factor that drives the expansion of this monocyte in vivo. It also remains to be determined whether bone marrow-derived Ym1 + monocytes differentiate into tissue-resident macrophages in inflamed organs.
In conclusion, we identified emerging monocytes that can act in immunoregulation and tissue repair. Elucidating the mechanism by which Ym1 + Ly6C hi monocytes control inflammation and tissue repair will enhance our understanding of the overall process of tissue injury and subsequent regeneration.
MATERIALS AND METHODS
Study design
The objective of this study was to identify a monocyte subset with a capacity to promote tissue regeneration in vivo. To achieve this goal, we designed and performed experiments in cellular immunology and animal study. The sample size (n = 3 to 8) for the in vivo experiments was determined to be the optimal size for statistical analysis while using an appropriate number of laboratory mice and allowing for independent repeats. Mice C57BL/6J (7 to 12 weeks old) mice were obtained from CLEA Japan Inc. All mice were housed under specific pathogen-free conditions in the Tokyo University of Pharmacy and Life Sciences animal facility. All experiments using the mice described herein were approved by the Tokyo University of Pharmacy and Life Sciences Animal Use Committee (L15-03, L16-14, and L17-24) and performed in accordance with applicable guidelines and regulations.
Reagents LPS (Escherichia coli, O111:B4) and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma-Aldrich. Ionomycin was purchased from Calbiochem. 7-Amino-actinomycin D (7-AAD), PerCP/ Cy5.5 Streptavidin, Brilliant Violet 421 Streptavidin, fixation buffer, Intracellular Staining Perm Wash Buffer, brefeldin A, and the FOXP3 Fix/Perm Buffer Set were purchased from BioLegend.
4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Dojindo. The Diff-Quik staining set was purchased from Sysmex. Ethidium monoazide bromide (EMA) was purchased from Thermo Fisher Scientific. Abs are summarized in table S1.
Cell isolation using magnetic sorting and cell sorter For monocyte isolation, bone marrow cells from Ym1-Venus mice were incubated with anti-CD16/32 and then with a cocktail of biotinylated anti-Lin (CD4, CD8, NK1.1, B220, and Ter119) Abs, followed by incubation with anti-biotin microbeads (Miltenyi, Germany). Lin + cells were depleted by magnetic sorting (AutoMACS Pro, Miltenyi). Lin − cells were stained with anti-CD115 and anti-Ly6C Abs and then fractionated by a cell sorter (SH800; Sony, Japan).
GP, cMoP, GMP, and MDP isolation was performed according to a method established previously (18, 31, 32) with slight modification. Bone marrow cells from Ym1-Venus mice were incubated with a cocktail of biotinylated anti-Lin (CD4, CD8, NK1.1, B220, Ter119, Sca-1, CD11b, and Gr-1) Abs, followed by incubation with anti-biotin microbeads (Miltenyi, Germany). Lin + cells were depleted by magnetic sorting (AutoMACS Pro, Miltenyi). Lin − cells were stained with anti-c-Kit, anti-CD16/32, anti-Ly6C, anti-Flt3, and anti-CD115 Abs and Brilliant Violet 421 streptavidin and then fractionated by a cell sorter (SH800; Sony, Japan were synthesized using ReverTra Ace (Toyobo, Japan). qRT-PCR was performed on cDNA using the THUNDERBIRD SYBR qPCR Mix (Toyobo, Japan). Expression levels were normalized to 18S ribosomal RNA. Primer sequences are summarized in table S2.
RNA sequencing
Sorted cells were lysed, and their total RNA was extracted with TRIzol LS reagent. Forty nanograms of total RNA was subjected to DNA library preparation for RNA sequencing (RNA-seq) analysis using the SureSelect Strand-Specific RNA Library Prep Kit for Illumina Multiplexed Sequencing (Agilent Technologies, CA). Sequencing was performed on a HiSeq 1500 sequencer (Illumina) in the 50-base pair single-end read mode. Data with the fragments per kilobase of exon per million reads were used for further analysis after mapping of the sequence reads.
In vitro monocyte stimulation
The sorted monocytes were stimulated for 24 hours with LPS (E. coli, O111:B4, 1 g/ml; Sigma, MO). Concentrations of IL-6, IL-12, TNF, IL-10, and Ym1 in the culture medium were quantitated with the enzyme-linked immunosorbent assay (ELISA) MAX Standard Kit (IL-6, IL-12, TNF, and IL-10; BioLegend, CA) or the ELISA system established in our laboratory (Ym1).
DSS-induced colitis
Mice were orally administered 2.0% DSS (36,000 to 50,000 Da; MP Biomedicals, CA) in drinking water for 5 days and in regular drinking water thereafter. Body weight was monitored daily or every other day for 12 days from the administration of DSS. In some experiments, 25ng/g body weight of DT was intraperitoneally injected on indicated days after the administration of DSS. For the depletion of neutrophils, 50 g of anti-Ly6G Ab (clone 1A8; Bio X Cell, NH) was intraperitoneally injected on days 8 and 10.
Assay for cMoP differentiation
Sorted cMoP (3000 cells per well in 96-well plates) was cultured with various cytokine combinations: 10% M-CSF (CMG14-12 culture medium), G-CSF (50 ng/ml; Chugai, Japan), recombinant mouse GM-CSF (20 ng/ml; BioLegend), IL-3 (10 ng/ml; Peprotech, NJ), recombinant mouse IL-4 (20 ng/ml; PeproTech, NJ), or recombinant mouse IL-10 (100 ng/ml; Miltenyi, Germany). The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin (Wako), and 10 mM Hepes. After a 72-hour culture, the cells were analyzed by flow cytometry.
Intracellular flow cytometry staining
For intracellular Foxp3 staining, CD4 T cells were enriched from the spleen by magnetic sorting. Those T cells were stimulated with immobilized anti-CD3e (10 g/ml) and anti-CD28 (5 g/ml) in the presence or absence of monocyte culture media for 72 hours in a 96-well plate. After stimulation, T cells were stained with anti-CD4 and EMA and then fixed and permeabilized in Fix/Perm Buffer (BioLegend). For intracellular IL-10 staining, CD4 T cells were enriched from the colon of DSS-administered mice by magnetic sorting. Those T cells were stimulated with PMA (100 ng/ml) and ionomycin (1.5 g/ml) for 3 hours in the presence of brefeldin A. After stimulation, those cells were fixed in fixation buffer and permeabilized in Intracellular Staining Perm Wash Buffer (BioLegend). Fixed/ permeabilized cells were stained with anti-Foxp3 or anti-IL-10 Ab, or isotype-matched control Ab, and analyzed by FACSVerse.
Statistical analysis
Data were analyzed either by analysis of variance (ANOVA), followed by multiple comparison or by the paired or unpaired t test with GraphPad Prism (GraphPad Software, CA). P < 0.05 was considered significant.
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